Investor Dashboard
Key financial KPIs at a glance — % against revenues in QuickBooks-statement style.
Revenue Mix · % of Top Line
Cost Structure · % of Operating Cost
Use of Funds · % of $4.0M Raise
Problem & Solution
Profitable chain of community pharmacies with telehealth integration · $5M Y5 EBITDA target
The Problem
GCC community pharmacy is dominated by 3 large chains operating cookie-cutter outlets and 4,000+ single-store independents lacking scale. Mid-market consumers want personalized care, telehealth integration, and same-day prescription fulfillment — none of which the current market structure delivers.
Our Solution
A regional pharmacy chain combining traditional retail dispensing with integrated telehealth consultation (in-store kiosks + app), chronic-care subscription programs, and a private-label SKU line at 22% higher margin. Each store is ~120 sqm with 4 FTEs and breaks even in month 8.
Market Opportunity
$18B GCC Pharmacy addressable today
GCC pharmacy retail growing 11% CAGR · telehealth-integrated segment growing 28% CAGR
Prescription dispensing (50% of revenue, ~22% gross margin), OTC and wellness (28%, ~38% margin), telehealth consultation fees (12%, ~65% margin), and chronic-care subscriptions (10%, ~55% margin). Average ticket ~$28, transactions per store per day ~95.
Financial Statements · % vs Revenue
QuickBooks-style readout — every line shown as percentage of its parent total.
Revenue Mix
| Revenue Stream | % of Revenue | Share |
|---|---|---|
| Prescription Dispensing | 50.0% | 50% |
| OTC & Wellness | 28.0% | 28% |
| Telehealth Consultations | 12.0% | 12% |
| Chronic-Care Subscriptions | 10.0% | 10% |
| Total Revenue | 100.0% | 100% |
Cost Structure
| Cost Line | % of Cost | Share |
|---|---|---|
| Cost of Goods (Drugs) | 55.0% | 55% |
| Store Staff | 14.0% | 14% |
| Rent & Utilities | 10.0% | 10% |
| Marketing & Loyalty | 6.0% | 6% |
| Telehealth Doctor Network | 8.0% | 8% |
| G&A | 7.0% | 7% |
| Total Operating Cost | 100.0% | 100% |
Use of Funds — $4.0M Raise
| Allocation | % of Raise | Share |
|---|---|---|
| 11 New Store Openings | 60.0% | 60% |
| Telehealth Platform Build-Out | 15.0% | 15% |
| Private-Label SKU Development | 12.0% | 12% |
| Pharmacy License & Compliance | 8.0% | 8% |
| Working Capital | 5.0% | 5% |
| Total Use of Funds | 100.0% | 100% |
Traction & Proof Points
- 3 stores operational, 2 profitable, 1 ramping (month 5)
- $2.4M run-rate revenue · 18% blended gross margin · -8% EBITDA (still investing)
- Telehealth consultation attach rate 14% of footfall · 4.7★ Google reviews avg
Moat & Exit Strategy
Defensible Moat
Telehealth integration creates a recurring revenue layer (chronic-care subs at 92% annual retention) that single-store independents can't replicate. Private-label SKUs lift gross margin 7pp vs branded-only stores. Multi-store dataset improves SKU mix per location, lifting same-store sales 18% in year 2.
Exit Path
Strategic acquisition by a regional pharmacy major (Aster, Life Pharmacy, Bin Sina) or healthcare conglomerate at 8–12x EBITDA, or roll-up into a healthcare REIT structure for stabilized cash yield within 5–7 years.
Key Risks
- GCC pharmacy regulation requires per-store license — slow expansion ceiling
- Margin compression as large chains cut prices to defend share
- Telehealth regulation evolving across UAE / KSA jurisdictions